Emerging targeted therapies for glioma

References

• Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008-2012. Neuro Oncol. 2015 Oct;17(Suppl 4):iv1–iv62.
   PubMed Web of Science ®Google Scholar
• Louis DN, Ohgaki H, Wiestler O, et al. WHO classification of tumours of the central nervous system, revised 4th ed. Lyon: International Agency for Research on Cancer; 2016.
   Google Scholar
• Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009 Feb;360(8):765–773.
   PubMed Web of Science ®Google Scholar
• Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science (New York, NY). 2008;321(5897):1807–1812.
   Google Scholar
• Sahm F, Reuss D, Koelsche C, et al. Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma. Acta Neuropathol. 2014;128(4):551–559.
   PubMed Web of Science ®Google Scholar
• Wen PY, Kesari S. Malignant gliomas in adults. N Engl J Med. 2008;359(5):492–507.
   PubMed Web of Science ®Google Scholar
• Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–996.
   PubMed Web of Science ®Google Scholar
• Schiff D. Low-grade gliomas. Continuum (Minneap Minn). 2015 Apr;21(2 Neuro–oncology):345–354.
   PubMedGoogle Scholar
• Buckner JC, Shaw EG, Pugh SL, et al. Radiation plus Procarbazine, CCNU, and Vincristine in low-grade glioma. N Engl J Med. 2016;374(14):1344–1355.
   PubMed Web of Science ®Google Scholar
• Sanson M, Marie Y, Paris S, et al. Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas. J Clin Oncol. 2009;27(25):4150–4154.
   PubMed Web of Science ®Google Scholar
• Brat DJ, Verhaak RGW, Aldape KD, et al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372(26):2481–2498.
   PubMed Web of Science ®Google Scholar
• Larjavaara S, Mäntylä R, Salminen T, et al. Incidence of gliomas by anatomic location. Neuro Oncol. 2007 Jul;9(3):319–325.
   PubMed Web of Science ®Google Scholar
• Hegi ME, Diserens A-C, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003.
   PubMed Web of Science ®Google Scholar
• Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine and vincristine in oligodendroglial tumors is associated with mutation of IDH. J Clin Oncol. 2014;32(8):783–790.
   PubMed Web of Science ®Google Scholar
• Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733–4740.
   PubMed Web of Science ®Google Scholar
• Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5):740–745.
   PubMed Web of Science ®Google Scholar
• Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010;28(11):1963–1972.
   PubMed Web of Science ®Google Scholar
• Wick W, Brandes AA, Gorlia T, et al. LB-05phase III trial exploring the combination of bevacizumab and lomustine in patients with first recurrence of a glioblastoma: the Eortc 26101 Trial. Neuro Oncol. 2015;17(suppl 5):v1–v1.
   PubMed Web of Science ®Google Scholar
• Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
   PubMed Web of Science ®Google Scholar
• Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):709–722.
   PubMed Web of Science ®Google Scholar
• Stupp R, Taillibert S, Kanner AA, et al. Maintenance therapy with tumor-treating fields plus temozolomide vs temozolomide alone for glioblastoma: a randomized clinical trial. JAMA. 2015;314(23):2535–2543.
   PubMed Web of Science ®Google Scholar
• Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality. Eur J Cancer. 2012;48(14):2192–2202.
   PubMed Web of Science ®Google Scholar
• Ostrom QT, Gittleman H, Liao P, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. Neuro Oncol. 2014;16(suppl_4):iv1–iv63.
   PubMed Web of Science ®Google Scholar
• Raizer JJ, Fitzner KA, Jacobs DI, et al. Economics of malignant gliomas: a critical review. J Oncol Pract/Am Soc Clin Oncol. 2014;11(1):e59–65.
   PubMed Web of Science ®Google Scholar
• Bernard-Arnoux F, Lamure M, Ducray F, et al. The cost-effectiveness of tumor-treating fields therapy in patients with newly diagnosed glioblastoma. Neuro Oncol. 2016;18(8):1129–1136.
   PubMed Web of Science ®Google Scholar
• McLendon R, Friedman A, Bigner D, et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 2008;455(7216):1061–1068.
   PubMed Web of Science ®Google Scholar
• Brennan C, Verhaak R, McKenna A, et al. The somatic genomic landscape of glioblastoma. Cell. 2013;155(2):462–477.
   PubMed Web of Science ®Google Scholar
• Sottoriva A, Spiteri I, Piccirillo SGM, et al. Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A. 2013;110(10):4009–4014.
   PubMed Web of Science ®Google Scholar
• Patel AP, Tirosh I, Trombetta JJ, et al. Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (New York, NY). 2014;344(6190):1396–1401.
   Google Scholar
• Prados MD, Byron SA, Tran NL, et al. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015;17(8):1051–1063.
   PubMed Web of Science ®Google Scholar
• Eckel-Passow JE, Lachance DH, Molinaro AM, et al. Glioma groups based on 1p/19q, IDH, and TERT promoter mutations in tumors. N Engl J Med. 2015;372(26):2499–2508.
   PubMed Web of Science ®Google Scholar
• Johnson BE, Mazor T, Hong C, et al. Mutational analysis reveals the origin and therapy-driven evolution of recurrent glioma. Science (New York, NY). 2014;343(6167):189–193.
   Google Scholar
• Piotrowska Z, Sequist LV. Epidermal growth factor receptor-mutant lung cancer: new drugs, new resistance mechanisms, and future treatment options. Cancer J. 2015;21(5):371–377.
   PubMed Web of Science ®Google Scholar
• Wong AJ, Bigner SH, Bigner DD, et al. Increased expression of the epidermal growth factor receptor gene in malignant gliomas is invariably associated with gene amplification. Proc Natl Acad Sci U S A. 1987;84(19):6899–6903.
   PubMed Web of Science ®Google Scholar
• Sugawa N, Ekstrand AJ, James CD, et al. Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. Proc Natl Acad Sci U S A. 1990 Nov;87(21):8602–8606.
   PubMed Web of Science ®Google Scholar
• Artega C. Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasia. Semin Oncol. 2002;29(5):3–9.
   Web of Science ®Google Scholar
• Reardon DA, Wen PY, Mellinghoff IK. Targeted molecular therapies against epidermal growth factor receptor: past experiences and challenges. Neuro Oncol. 2014;16(August):viii7–viii13.
   PubMed Web of Science ®Google Scholar
• Celldex. Data Safety and Monitoring Board Recommends Celldex ‘ s Phase 3 Study of RINTEGA ® (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease Compa; 2016
   Google Scholar
• Schafer N, Gielen GH, Kebir S, et al. Phase I trial of dovitinib (TKI258) in recurrent glioblastoma. J Cancer Res Clin Oncol. 2016;142(7):1–9.
   PubMed Web of Science ®Google Scholar
• Li X, Wu C, Chen N, et al. PI3K /Akt /mTOR signaling pathway and targeted therapy for glioblastoma. Oncotarget. 2016;7:22.
   Web of Science ®Google Scholar
• Duzgun Z, Eroglu Z, Biray Avci C. Role of mTOR in glioblastoma. Gene. 2016;575(2):187–190.
   PubMed Web of Science ®Google Scholar
• Sami A, Karsy M. Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding. Tumor Biol. 2013;34(4):1991–2002.
   PubMed Web of Science ®Google Scholar
• England B, Huang T, Karsy M. Current understanding of the role and targeting of tumor suppressor p53 in glioblastoma multiforme. Tumor Biol. 2013;34(4):2063–2074.
   PubMed Web of Science ®Google Scholar
• Merlo A. Genes and pathways driving glioblastomas in humans and murine disease models. Neurosurg Rev. 2003;26(3):145–158.
   PubMed Web of Science ®Google Scholar
• Weathers S-P, de Groot JVEGF. Manipulation in glioblastoma. Oncology (Williston Park, NY). 2015;29(10):720–727.
   PubMed Web of Science ®Google Scholar
• Lu-Emerson C, Duda DG, Emblem KE, et al. Lessons from anti-vascular endothelial growth factor and anti-vascular endothelial growth factor receptor trials in patients with Glioblastoma. J Clin Oncol. 2015;33(10):1197–1213.
   PubMed Web of Science ®Google Scholar
• Khasraw M, Lee A, McCowatt S, et al. Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. J Neurooncol. 2016;128(1):1–9.
   PubMed Web of Science ®Google Scholar
• Sheehan JP, Shaffrey ME, Gupta B, et al. Improving the radiosensitivity of radioresistant and hypoxic glioblastoma. Future Oncol. 2010;6(10):1591–1601.
   PubMed Web of Science ®Google Scholar
• Dang L, White DW, Gross S, et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462(7274):739–744.
   PubMed Web of Science ®Google Scholar
• Phillips AC, Boghaert ER, Vaidya KS, et al. ABT-414, an antibody-drug conjugate targeting a tumor-selective EGFR epitope. Mol Cancer Ther. 2016;128(2):438–445.
   Google Scholar
• Zahonero C, Aguilera P, Ramirez-Castillejo C, et al. Preclinical test of dacomitinib, an irreversible EGFR inhibitor, confirms its effectiveness for glioblastoma. Mol Cancer Ther. 2015;14(7):1548–1558.
   PubMed Web of Science ®Google Scholar
• Singh D, Chan JM, Zoppoli P, et al. Transforming fusions of FGFR and TACC genes in human glioblastoma. Science (New York, NY). 2012;337(6099):1231–1235.
   Google Scholar
• Khan Z, Andersson S, Yin S, et al. Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastoma. Seven. 2010;12(1):19–27.
   Google Scholar
• Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997;57(23):5391–5398.
   PubMed Web of Science ®Google Scholar
• Wen PY, Schiff D, Cloughesy TF, et al. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011;13(4):437–446.
   PubMed Web of Science ®Google Scholar
• Pitz MW, Eisenhauer EA, MacNeil MV, et al. Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 2015;17(9):1270–1274.
   PubMed Web of Science ®Google Scholar
• Wen PY, Yung WKA, Mellinghoff IK, et al. Phase II trial of the phosphatidyinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma. J Clin Oncol. 2014;32(15):suppl(abstract 2019)-suppl (abstract 19).
   Web of Science ®Google Scholar
• Wen PY, Cloughesy TF, Olivero A, et al. A first-in-human phase 1 study to evaluate the brain-penetrant PI3K/mTOR inhibitor GDC-0084 in patients with progressive or recurrent high-grade glioma. J Clin Oncol. 2016;34(15):suppl(abstract 2012)-suppl (abstract 12).
   Google Scholar
• Ma DJ, Galanis E, Anderson SK, et al. A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. Neuro Oncol. 2015;17(9):1261–1269.
   PubMed Web of Science ®Google Scholar
• Lee EQ, Kuhn J, Lamborn KR, et al. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American brain tumor consortium study 05-02. Neuro Oncol. 2012;14(12):1511–1518.
   PubMed Web of Science ®Google Scholar
• Patnaik A, Rosen LS, Tolaney SM, et al. Efficacy and safety of abemaciclib, an inhibitor of cdk4 and cdk6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors. Cancer Discov. 2016;6(7):740–754.
   PubMed Web of Science ®Google Scholar
• Sarcar B, Kahali S, Prabhu A, et al. Targeting radiation-induced G2 checkpoint activation with the wee-1 inhibitor MK-1775 in glioblastoma cell lines. Mol Cancer Ther. 2011;10(12):2405–2414.
   PubMed Web of Science ®Google Scholar
• Werner LR, Huang S, Francis DM, et al. Small molecule inhibition of MDM2-p53 interaction augments radiation response in human tumors. Mol Cancer Ther. 2015;14(9):1994–2004.
   PubMed Web of Science ®Google Scholar
• Kloepper J, Riedemann L, Amoozgar Z, et al. Ang-2/VEGF bispecific antibody reprograms macrophages and resident microglia to anti-tumor phenotype and prolongs glioblastoma survival. Proc Natl Acad Sci U S A. 2016;113(16):4476–4481.
   PubMed Web of Science ®Google Scholar
• Fujii T, Khawaja MR, DiNardo CD, et al. Targeting isocitrate dehydrogenase (IDH) in cancer. Discov Med. 2016;21(117):373–380.
   PubMed Web of Science ®Google Scholar
• Panknin O, Pusch S, Herbst L, et al. Abstract 2645: BAY 1436032: A highly selective, potent and orally available inhibitor of mutant forms of IDH1. Cancer Res. 2016;76(14Supplement):2645 LP–45.
   Google Scholar
• Seymour T, Nowak A, Kakulas F. Targeting aggressive cancer stem cells in glioblastoma. Front Oncol. 2015;5(July):159–59.
   PubMed Web of Science ®Google Scholar
• Wei L, Su Y-K, Lin C-M, et al. Preclinical investigation of ibrutinib, a Bruton’s kinase tyrosine (Btk) inhibitor, in suppressing glioma tumorigenesis and stem cell phenotypes. Oncotarget. 2016;7(43):69961–69975.
   PubMed Web of Science ®Google Scholar
• Xu R, Shimizu F, Hovinga K, et al. Molecular and clinical effects of notch inhibition in glioma patients: a phase 0/I trial. Clin Cancer Res. 2016;22(19):4786–4796.
   PubMed Web of Science ®Google Scholar
• Lassen UN, Mau-Soerensen M, Kung AL, et al. A phase 2 study on efficacy, safety and intratumoral pharmacokinetics of oral selinexor (KPT-330) in patients with recurrent glioblastoma (GBM). J Clin Oncol. 2015;33(15):suppl(abstract 2044)-suppl (abstract 44).
   Web of Science ®Google Scholar
• Ene CI, Fine HA. Many tumors in one: a daunting therapeutic prospect. Cancer Cell. 2011;20(6):695–697.
   PubMed Web of Science ®Google Scholar
• Snuderl M, Fazlollahi L, Le LP, et al. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 2011;20(6):810–817.
   PubMed Web of Science ®Google Scholar